Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Jeffrey Vaks"'
Autor:
Fernando Lopez-Rios, Barbara Angulo, Belen Gomez, Debbie Mair, Rebeca Martinez, Esther Conde, Felice Shieh, Jeffrey Vaks, Rachel Langland, H Jeffrey Lawrence, David Gonzalez de Castro
Publikováno v:
PLoS ONE, Vol 8, Iss 1, p e53733 (2013)
The cobas 4800 BRAF V600 Mutation Test is a CE-marked and FDA-approved in vitro diagnostic assay used to select patients with metastatic melanoma for treatment with the selective BRAF inhibitor vemurafenib. We describe the pre-approval validation of
Externí odkaz:
https://doaj.org/article/8b7c7ba839a0413692b4b920d1c8bd92
Autor:
Michael J. Santulli, Parichehr Hemyari, Nancy Schoenbrunner, Matthias Rullkoetter, Jeffrey Vaks
Publikováno v:
The Journal of Applied Laboratory Medicine. 1:260-270
Background Limit of detection (LOD) is an important performance characteristic of clinical laboratory tests. Verification, as recommended by the CLSI EP17-A2 guideline, is done by testing a sample with a claimed LOD concentration. Claimed LOD is veri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9a794ba2a7c07fecae93b73a35354f7
https://doi.org/10.1373/jalm.2016.020735
https://doi.org/10.1373/jalm.2016.020735
Autor:
Susan A, Galel, Toby L, Simon, Phillip C, Williamson, James P, AuBuchon, Dan A, Waxman, Yasuko, Erickson, Rasa, Bertuzis, John R, Duncan, Khushbeer, Malhotra, Jeffrey, Vaks, Nancy, Huynh, Lisa Lee, Pate
Publikováno v:
Transfusion. 58(3)
Use of nucleic acid testing (NAT) in donor infectious disease screening improves transfusion safety. Advances in NAT technology include improvements in assay sensitivity and system automation, and real-time viral target discrimination in multiplex as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::17f34d50235830f134a0eddd6de28294
https://pubmed.ncbi.nlm.nih.gov/29250788
https://pubmed.ncbi.nlm.nih.gov/29250788
Autor:
Belen Gomez, David Gonzalez de Castro, Rebeca Martinez, Julie Tsai, Robert Current, H. Jeffrey Lawrence, Barbara Angulo, D. Mair, Fernando Lopez-Rios, Esther Conde, Felice Shieh, Jeffrey Vaks
Publikováno v:
Journal of Clinical Pathology
AimTo conduct a methods correlation study of three different assays for the detection of mutations atEGFRgene in human formalin-fixed paraffin-embedded tumour (FFPET) specimens of non-small cell lung carcinomas (NSCLC).MethodsWe conducted a 2-site me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0d6163ee7ad7d0bcafda19fad03d91d
https://doi.org/10.1136/jclinpath-2012-201240
https://doi.org/10.1136/jclinpath-2012-201240
Publikováno v:
Journal of Clinical Virology. 52:S77-S82
Significant advancements in molecular diagnostics have been made since the inception and application of PCR-based technologies in clinical diagnostic laboratories and the management of HIV-1 infected patients. More recently, real-time PCR has improve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98c36878a7c06ef4adffc1e1e5d9b733
https://doi.org/10.1016/j.jcv.2011.09.015
https://doi.org/10.1016/j.jcv.2011.09.015
Autor:
Debbie Mair, H. Jeffrey Lawrence, Belen Gomez, Fernando Lopez-Rios, Jeffrey Vaks, Rebeca Martinez, Felice Shieh, David Gonzalez de Castro, Rachel Langland, Barbara Angulo, Esther Conde
Publikováno v:
PLoS ONE
PLoS ONE, Vol 8, Iss 1, p e53733 (2013)
PLoS ONE, Vol 8, Iss 1, p e53733 (2013)
Background: The cobas 4800 BRAF V600 Mutation Test is a CE-marked and FDA-approved in vitro diagnostic assay used to select patients with metastatic melanoma for treatment with the selective BRAF inhibitor vemurafenib. We describe the pre-approval va
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c6c2f680a5d5b7f4885736c75e655b2
http://europepmc.org/articles/PMC3542342
http://europepmc.org/articles/PMC3542342